Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 10/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986259 | 0.84 | HPGD (0.49) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL3468980 | 0.82 | HPGD (0.49) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL6037012 | 0.82 | ALDH1A1 (0.56) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL4802179 | 0.81 | HPGD (0.51) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL10774632 | 0.81 | HPGD (0.51) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL1987812 | 0.80 | HPGD (0.54) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL37698 | 0.80 | HPGD (0.54) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL3282095 | 0.79 | HPGD (0.51) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL2877720 | 0.79 | HPGD (0.51) | HPGDALDH1A1ALOX12BRCA1HSD17B10 | |
| SCHEMBL7907421 | 0.79 | ALDH1A1 (0.53) | HPGDALDH1A1ALOX12BRCA1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050118605-A9 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050037370-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | BAKER BRENDA F (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050032069-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2004044245-A1 | OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE AND GUANINE AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-5552540-A | NONRADIOACTIVE LABELS | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 1996-09-03 | — | — | US | disclosed |
| EP-0366685-B1 | NUCLEOSIDE DERIVATIVES | FLOREY HOWARD INST (AU) | 1994-10-19 | — | — | EP | disclosed |
| EP-0366685-A4 | NUCLEOSIDE DERIVATIVES | — | 1991-03-20 | — | — | EP | disclosed |
| EP-0366685-A1 | NUCLEOSIDE DERIVATIVES. | FLOREY HOWARD INST (AU) | 1990-05-09 | — | — | EP | disclosed |
| WO-1988010264-A1 | NUCLEOSIDE DERIVATIVES | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY (AU) | 1988-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037370-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | RNMT, RRBP1, G3BP1 | HPGD 4184/4885ALDH1A1 4679/4885ALOX12 4266/4885 |
| US-20050118605-A9 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | RNMT, RRBP1, G3BP1 | HPGD 4184/4885ALDH1A1 4679/4885ALOX12 4266/4885 |
| US-20050032069-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | RNMT, RRBP1, G3BP1 | HPGD 4184/4885ALDH1A1 4679/4885ALOX12 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.